1、Legend Biotech Reports Third Quarter 2025 Results and Recent HighlightsNovember 12,2025CARVYKTI(ciltacabtagene autoleucel;cilta-cel)net trade sales of approximately$524 millionEC and U.S.FDA label updates for CARVYKTI to include overall survival benefit versus standard of careOver 9,000 patients tre

2、ated to dateInitiated CARVYKTI commercial production at Tech Lane facility in BelgiumCash and cash equivalents,and time deposits of approximately$1.0 billion,as of September 30,2025SOMERSET,N.J.,Nov.12,2025(GLOBE NEWSWIRE)-Legend Biotech Corporation(NASDAQ:LEGN)(Legend Biotech),a global leader in ce

3、lltherapy,today reported its third quarter 2025 unaudited financial results and key corporate highlights.“CARVYKTI continues to deliver strong sequential revenue growth,driven by sustained demand and recognition of its unprecedented survival benefit,now supported by five-year progression free data f

4、rom the CARTITUDE-1 study,”said Ying Huang,Ph.D.,Chief Executive Officer of Legend Biotech.“CARVYKTI remains the market leader in multiple myeloma CAR-T as the only approved therapy for second-line treatment,now with a survival benefitlabel.With commercial supply from our Tech Lane facility in Belgi

5、um now supporting the European market,and our Raritan physical expansion ontrack for approval by year end,we believe we are poised to achieve CARVYKTI profitability by year-end and company-wide profitability in 2026.”Regulatory UpdatesThe U.S.Food and Drug Administration(FDA)and the European Commiss

6、ion(EC)approved label updates forCARVYKTI to include the overall survival (OS)data from the landmark Phase 3 CARTITUDE-4 study,whichdemonstrated a statistically significant OS benefit for CARVYKTI versus standard therapies of pomalidomide,bortezomiband dexamethasone(PVd)or daratumumab,pomalidomide a